Idp-121

Multiple Myeloma (MM)

IDP Discovery Pharma S.L.Phase 1/2Active

CC

45/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 33/ 100
Competitive Position: 81/ 100

Competitive context

497 Active assets in the Multiple Myeloma (MM) cohort.

Asset / Sponsor	Phase	Rating
FILGRASTIM Jonsson Comprehensive Cancer Center	Phase 4	BBB
Inno-206 University of Arkansas	Phase 3	BBB
Hyaluronidase fihj Massachusetts General Hospital	Phase 4	BBB
Busulphan M.D. Anderson Cancer Center	Phase 4	BBB
Filanesib PETHEMA Foundation	Phase 2	BBB

View all 50 →

Same molecule, other indications

Idp-121 is also rated in:

high-grade B-cell lymphoma double-hit/triple-hitDormant

CCC

Indicative ·

48 / 100

diffuse large B-cell lymphomaDormant

CC

Indicative ·

47 / 100

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant

CC

Indicative ·

47 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.